Zentalis Pharmaceuticals (ZNTL) Minority Interest (2019 - 2023)

Zentalis Pharmaceuticals' Minority Interest history runs 5 years deep, the most recent figure standing at $107000.0 for Q4 2023.

• On a quarterly basis, Minority Interest fell 51.58% year-over-year to $107000.0 in Q4 2023; TTM through Dec 2023 was $107000.0, a 51.58% decrease from a year earlier, with the FY2023 full-year figure at $107000.0, down 51.58% from the prior year.
• Minority Interest retreated to $107000.0 in Q4 2023 per ZNTL's latest filing, from $129000.0 in the prior quarter.
• Across five years, Minority Interest topped out at $24.8 million in Q4 2020 and bottomed at $107000.0 in Q4 2023.
• The 5-year median for Minority Interest is $368000.0 (2022), against an average of $5.9 million.
• Across the five-year window, Minority Interest surged 263.51% in 2020 and sank 98.6% in 2022, its largest moves.
• Year by year, Minority Interest stood at $6.8 million in 2019, then jumped by 263.51% to $24.8 million in 2020, then slumped by 97.87% to $528000.0 in 2021, then plunged by 58.14% to $221000.0 in 2022, then slumped by 51.58% to $107000.0 in 2023.
• Per Business Quant, the three latest ZNTL Minority Interest figures stand at $107000.0 (Q4 2023), $129000.0 (Q3 2023), and $141000.0 (Q2 2023).